The companies and brands that innovate in anticipation of the impact of these drugs will find themselves awash in new interest from those who feel a new sense of control and autonomy in their choices: brands that speak to their aspirational selves, affirm their commitments to living better, and underscore that behavior-modifying medications are only step one of a lifelong shift that includes their category and brand
Data presented at the American Academy of Orthopedic Surgeons Annual Meeting reported on patients with obesity with or without diabetes, using GLP-1 agonists who were found to have statistically significantly increased rates of injuries to tendons
The literature was searched in PubMed/MEDLINE, Embase, Web of Science, and Google Scholar from database inception to 10 March 2026, using terms related to knee osteoarthritis, obesity, GLP-1 receptor agonists, incretin-based therapies, GLP-1 receptor biology, pharmacology, molecular mechanisms, inflammatory signaling, NF-B, NLRP3 inflammasome, macrophage polarization, weight loss, arthroplasty, perioperative management, sarcopenia, safety, and cost-effectiveness
As an advocate for meaningful change in how obesity is understood, Sophie works to reduce stigma and raise awareness of the condition as an illness
Peer-reviewed clinical trials in the T4 family (RGN-259 ophthalmic, RGN-352 cardiac) used full-length T4
Effects of Thymus vulgaris oil on sodium hypochlorite-induced damage in rats
